valtricom
krka, d.d., novo mesto - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 5 mg/160 mg/25 mg - valsartan, amlodipine and hydrochlorothiazide
valtricom
krka, d.d., novo mesto - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 10 mg/160 mg/25 mg - valsartan, amlodipine and hydrochlorothiazide
valtricom
krka, d.d., novo mesto - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 10 mg/320 mg/25 mg - valsartan, amlodipine and hydrochlorothiazide
dippvol
sandoz d.d. - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 5 mg/160 mg/12,5 mg - valsartan, amlodipine and hydrochlorothiazide
dippvol
sandoz d.d. - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 10 mg/160 mg/12,5 mg - valsartan, amlodipine and hydrochlorothiazide
dippvol
sandoz d.d. - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 5 mg/160 mg/25 mg - valsartan, amlodipine and hydrochlorothiazide
dippvol
sandoz d.d. - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 10 mg/160 mg/25 mg - valsartan, amlodipine and hydrochlorothiazide
dippvol
sandoz d.d. - amlodipinas/valsartanas/hidrochlorotiazidas - plėvele dengtos tabletės - 10 mg/320 mg/25 mg - valsartan, amlodipine and hydrochlorothiazide
jaypirca
eli lilly nederland b.v. - pirtobrutinib - limfoma, mantle-cell - baltymų kinazės inhibitoriai - treatment of mantle cell lymphoma (mcl).
zydelig
gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.